Kevin Wasserstein is a co-founder of Avation Medical, and has served on its board since inception. Kevin specializes in investing in, and building, medical device companies through their entire life cycle, from concept to commercialization.
Currently, Kevin serves as Corporate Vice President, Ventures, at Boston Scientific, where he provides leadership and oversight of Boston Scientific’s Venture investment activity, including more than 50 portfolio company investments spanning all stages of development.
Kevin currently serves, or has served, in board or advisory roles with companies which include: Acclarent (acquired: Johnson & Johnson), Autonomic Technologies, Ebb Therapeutics (acquired), Eargo (NASDAQ: EAR), LipoSonix (acquired: Medicis), Lutonix (acquired: Bard), Microfabrica (acquired: TechnoProbe), Neoguide (acquired: Intuitive Surgical), Oculeve (acquired: Allergan), Respicardia (acquired: Sorin), Rox Medical, Second Sight Medical (NASDAQ: EYES), Sollis Therapeutics, St. Francis Medical (acquired: Kyphon), The Innovation Factory.
Kevin previously held numerous operating leadership roles, including marketing and business development at Guidant Corporation, corporate business development and ventures at Guidant Compass, business development at Heartstream, and engineering development and management at Hughes Aircraft Company.
Kevin holds both Bachelor’s and Master’s degrees in Mechanical Engineering, specializing in product design, as well as an MBA, from Stanford University.